Saturday - June 7, 2025
ENHERTU Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2-Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase III Trial
May 08, 2025
WILMINGTON, Delaware, May 8 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ENHERTU (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial

AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP
. . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products